Treatment of Benign Prostatic Hyperplasia by Natural Drugs

Csikós, Eszter and Horváth, Adrienn and Ács, Kamilla and Papp, Nóra and Balázs, Viktória Lilla and Horváth, Györgyi and Farkas, Ágnes (2021) Treatment of Benign Prostatic Hyperplasia by Natural Drugs. MOLECULES, 26 (23). pp. 1-32. ISSN 1420-3049

Preview

Text molecules-26-07141-v2.pdf Available under License Creative Commons Attribution. Download (575kB) | Preview

Abstract

Benign prostatic hyperplasia (BPH) is one of the most common urinary diseases affecting men, generally after the age of 50. The prevalence of this multifactorial disease increases with age. With aging, the plasma level of testosterone decreases, as well as the testosterone/estrogen ratio, resulting in increased estrogen activity, which may facilitate the hyperplasia of the prostate cells. Another theory focuses on dihydrotestosterone (DHT) and the activity of the enzyme 5α-reductase, which converts testosterone to DHT. In older men, the activity of this enzyme increases, leading to a decreased testosterone/DHT ratio. DHT may promote prostate cell growth, resulting in hyperplasia. Some medicinal plants and their compounds act by modulating this enzyme, and have the above-mentioned targets. This review focuses on herbal drugs that are most widely used in the treatment of BPH, including pumpkin seed, willow herb, tomato, maritime pine bark, Pygeum africanum bark, rye pollen, saw palmetto fruit, and nettle root, highlighting the latest results of preclinical and clinical studies, as well as safety issues. In addition, the pharmaceutical care and other therapeutic options of BPH, including pharmacotherapy and surgical options, are discussed, summarizing and comparing the advantages and disadvantages of each therapy.

Actions (login required)

Edit Item